8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.

Xia P, Zheng Y, Dong L, Tian C

Bioeffects Seen

Authors not listed · 2021

Share:

Study shows 50% improvement in nasopharyngeal cancer outcomes with additional treatment in region most exposed to cell phone radiation.

Plain English Summary

Summary written for general audiences

This study examined whether adding a low-dose chemotherapy drug (capecitabine) after standard radiation treatment could prevent cancer recurrence in 406 patients with advanced nasopharyngeal cancer. After 3 years, patients receiving the additional drug had significantly better survival rates (85.3% vs 75.7%) with manageable side effects. The results suggest this approach could become a new standard treatment for this aggressive cancer.

Why This Matters

While this study focuses on cancer treatment rather than EMF exposure, it's worth noting that nasopharyngeal carcinoma occurs in the same anatomical region where cell phone radiation is most concentrated during calls. The nasopharynx sits directly behind the nose and receives the highest radiation dose when you hold a phone to your ear. Some research has suggested potential links between heavy cell phone use and this specific type of cancer, though the evidence remains limited. What's particularly relevant is that this study demonstrates how even small interventions can significantly impact survival rates in cancers affecting areas of high EMF exposure. The 50% reduction in treatment failure shows how critical it is to address all potential risk factors for cancers in EMF-sensitive regions. While we can't prevent all cancers, we can certainly reduce our unnecessary radiation exposure by using speakerphone, texting instead of calling, and keeping devices away from our heads during sleep.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2021). Xia P, Zheng Y, Dong L, Tian C.
Show BibTeX
@article{xia_p_zheng_y_dong_l_tian_c_ce4596,
  author = {Unknown},
  title = {Xia P, Zheng Y, Dong L, Tian C},
  year = {2021},
  doi = {10.1016/S0140-6736(21)01123-5},
  
}

Quick Questions About This Study

Nasopharyngeal carcinoma is a cancer that develops in the nasopharynx, the area behind the nose and above the throat. This is the same region that receives the highest concentration of radiation when holding a cell phone to your ear during calls.
After 3 years, 85.3% of patients receiving capecitabine remained cancer-free compared to 75.7% in the control group. This represents a 50% reduction in the risk of cancer recurrence or death from any cause.
The most common serious side effect was hand-foot syndrome, affecting 9% of patients with grade 3 severity. Overall, 17% experienced grade 3 adverse events compared to 6% in the observation group. No treatment-related deaths occurred.
Patients took oral capecitabine at 650 mg/m² twice daily for one full year. Treatment began 12-16 weeks after completing their final radiotherapy dose, allowing time for recovery from initial treatment effects.
The significant improvement in failure-free survival with manageable side effects suggests this could become a new standard treatment. The results support using metronomic chemotherapy as adjuvant therapy for high-risk nasopharyngeal carcinoma patients.